Hanshang Group Co.Ltd(600774) “big health + big business” has been developing steadily, and a brilliant report card of strategic transformation has been handed over. On March 31, Hanshang Group Co.Ltd(600774) published the annual report of 2021, which showed that the company achieved an operating revenue of 1.475 billion yuan, an increase of 197.91% year-on-year; The net profit was 856791 million yuan, an increase of 88.36% year-on-year, the best performance in history.
Since Zhuoer holding became the “owner” Hanshang Group Co.Ltd(600774) of the company, the company has firmly adhered to the dual main business development strategy, combined the business with the pharmaceutical industry, steadily improved the commercial operation efficiency, continuously consolidated the business foundation of chemical medicine, Chinese patent medicine and medical devices, synchronously expanded the business layout of assisted reproduction, biomedical materials and medical services, and achieved remarkable results in transformation and development. The company has a clear business model and opened a growth channel for performance.
In 2021, the company’s pharmaceutical business grew steadily, the growth power of star products of chemical drugs and traditional Chinese medicine was strong, and retail sales continued to develop. Dikang pharmaceutical achieved an operating revenue of 1.138 billion yuan and a net profit of 123 million yuan. Its operating performance reached the best in history and consolidated the foundation of the pharmaceutical industry.
The company’s high-tech medical device business based on biomedical materials maintains a leading position in the industry. The absorbable medical membrane and absorbable fracture internal fixation screw products made of polylactic acid materials rank among the top three in the market of the same industry, and continue to lead the technological development and iterative innovation of absorbable medical devices.
At the same time, the company accelerated the expansion of large health segments. In the field of assisted reproduction, with Wuhan Tongji reproductive medicine hospital as the core, it increased its capital and took shares in Shenzhen yinguan Biotechnology Co., Ltd., explored the research and development of stem cell products related to assisted reproduction, promoted the construction of the whole industrial chain of reproductive medicine, and received high attention from the market. In the field of biomedical materials, relying on the technical reserve of absorbable medical materials, promote the R & D and industrial transformation of relevant medical device products. The company has improved the ecological chain of large health industry, and health drinks such as “shangshangqing drink” plant beverage and “shangshangquan drink” natural mountain spring water containing selenium have been freshly listed, with good market response.
In the same period, due to the gradual recovery of consumption and business activities, the company’s commercial retail and exhibition business increased by 37.02% and 75.78% respectively, and the operation continued to improve.
Hanshang Group Co.Ltd(600774) said it would continue to promote the development model of “big health + big business”, accelerate the reconstruction and upgrading of commercial projects, improve the operating efficiency of the commercial sector, promote the rapid growth of the pharmaceutical sector through internal cultivation and external mergers and acquisitions, and seek new breakthroughs in new retail, medicine, medical devices, medical services, assisted reproduction, health drinks and other fields.
